Date & Location: Friday, September 19, 2025, 8:30 AM – 1:00 PM, Virtual
CVD is the leading cause of death in the US. Hypertension and diabetes are among the foremost risk factors for the development of CVD, stroke, peripheral artery disease, and heart attack. This program will provide an overview of recent advances that target the underlying pathophysiology of cardiovascular disease. The focus of the program will be on the new therapeutic strategies for hypertension, hyperlipidemia, and CKD.
Learning Objectives
After completing this activity, participants should be able to:
Select appropriate medications to reduce adverse cardiovascular outcomes in high-risk and vulnerable populations
Identify appropriate blood pressure treatment strategies in high-risk patient populations
Review the controversies regarding novel therapies for CVD prevention.
Provide the best screening options for hypertension
Apply appropriate pharmacologic and non-pharmacologic approaches to cardiovascular risk prevention
+ Topics:
Friday, September 19, 2025
8:15AM – 8:30AM Sign into Virtual Platform
8:30AM – 8:35AM Welcome & Introductions Debbie Cohen Stein, MD
SESSION I: HYPERTENSION UPDATES
8:35AM – 8:45AM What’s New in Hypertension Guidelines Jordana Cohen, MD
8:45AM – 8:55AM Peripartum Hypertension Management Monika Sanghavi, MD
8:55AM – 9:05AM Optimizing Antihypertensive Treatment Selection in Patients with CKD Matthew Denker, MD
9:05AM – 9:15AM Fibromuscular Dysplasia and Spontaneous Coronary Artery Dissection Jennifer Lewey, MD
9:15AM – 9:45AM Q&A Panel and Case Presentation with the Speakers Hanaro E Lee, CRNP RN (Moderator)
9:45AM – 9:50AM Break
SESSION II: PREVENTIVE CARDIOLOGY – UNDERSTANDING RISK AND EVALUATION
9:50AM – 10:00AM How Do I Approach Triglycerides? dan E soffer, MD
10:00AM – 10:10AM Prediabetes: When to Treat and with What? Benjamin Cooperberg, MD
10:10AM – 10:20AM Advanced Lipid Testing/Lipoproteins and Discordance Douglas S Jacoby, MD
10:20AM – 10:50AM Q&A Panel and Case Presentation with the Speakers Emma MacAllister, CRNP
10:50AM – 10:55AM Break
SESSION III: POTASSIUM AND HYPERTENSION
10:55AM – 11:05AM Potassium Management in the Setting of Blood Pressure Medications – When to Check and How to Titrate Accordingly John Demko, MD
11:05AM – 11:15AM Aldosterone Synthase Inhibitors – New Data and Considerations Debbie Cohen Stein, MD
11:15AM – 11:25AM Dietary Potassium and Potassium-based Salt-substitutes Rachel S Shulman, MSCE
11:25AM – 11:55AM Q&A Panel and Case Presentation with the Speakers Maria L Bonanni, CRNP (Moderator)
11:55AM – 12:00PM Break
SESSION IV: NOVEL THERAPIES AND INDICATIONS
12:00PM – 12:10PM LPa-lowering Drugs Archna Bajaj, MD, MSCE
12:10PM – 12:20PM GLP1RA/Incretin Therapy: Updated Indications and Real-World Application Riya Patel, PharmD
12:20PM – 12:30PM Renal Denervation: Management and Setting Expectations Before and After Denervation Taisei Kobayashi, MD
12:30PM – 1:00PM Q&A Panel and Case Presentation with the Speakers Gayley B Webb, CRNP RN





Reviews
There are no reviews yet.